Physician’s WeeklyTranexamic Acid Cuts Major Bleeding Risk in Urologic Surgery

⚠️ Small Study / Early Comparative Evidence

Perioperative bleeding remains a common complication of urologic surgery and can increase transfusion requirements, reinterventions, length of stay, and healthcare utilization. Investigators conducted a prespecified analysis of 1,124 patients within the international randomized POISE-3 trial to evaluate whether perioperative tranexamic acid (TXA) reduces bleeding events in patients undergoing a broad range of urologic procedures. Participants received either intravenous TXA (1 g at the beginning and end of surgery) or placebo. The cohort included robotic, laparoscopic, open, transurethral, and percutaneous procedures, with more than half of patients having active cancer.

Clinical Considerations

• The primary composite bleeding outcome occurred in 8.1% of TXA-treated patients versus 10.9% with placebo.
• Major bleeding occurred in 6.1% versus 9.5%, representing an approximate 37% relative risk reduction with TXA.
• Lower major bleeding rates were accompanied by numerically lower transfusion requirements, suggesting reduced exposure to blood products.
• The primary thrombotic composite endpoint occurred in 12.1% of TXA patients and 10.9% of placebo patients, without a statistically significant difference.
• Rates of stroke (2 events per group) and symptomatic venous thromboembolism (3 events per group) were low and identical between study arms.
• Treatment effects appeared consistent across surgical approach, cancer status, and preoperative antithrombotic use.

Practice Applications

• Consider TXA as a potential bleeding-reduction strategy for urologic surgery patients at elevated bleeding risk.
• Interpret the findings within the context of a subgroup analysis rather than a urology-specific dedicated randomized trial.
• Recognize that no clear thrombotic safety signal emerged, although larger studies may be needed to better define risk.
• Evaluate transfusion reduction as a potentially important perioperative outcome when assessing TXA use in surgical patients.
• Monitor future guideline updates as additional procedure-specific evidence becomes available.